131 related articles for article (PubMed ID: 14641795)
1. Use of alpha-blockers and the risk of hip/femur fractures.
Souverein PC; Van Staa TP; Egberts AC; De la Rosette JJ; Cooper C; Leufkens HG
J Intern Med; 2003 Dec; 254(6):548-54. PubMed ID: 14641795
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of modified release alpha-blocker exposure in elderly patients with fractures.
Hall GC; McMahon AD
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):901-7. PubMed ID: 17443863
[TBL] [Abstract][Full Text] [Related]
3. Risk of hip/femur fractures during the initiation period of α-adrenoceptor blocker therapy among elderly males: a self-controlled case series study.
Lai CL; Kuo RN; Chen HM; Chen MF; Chan KA; Lai MS
Br J Clin Pharmacol; 2015 Nov; 80(5):1208-18. PubMed ID: 25924025
[TBL] [Abstract][Full Text] [Related]
4. Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands.
de Vries F; Souverein PC; Cooper C; Leufkens HG; van Staa TP
Calcif Tissue Int; 2007 Feb; 80(2):69-75. PubMed ID: 17308987
[TBL] [Abstract][Full Text] [Related]
5. The risk of bone fracture after long-term risperidone exposure is not increased compared to other atypical antipsychotics: A retrospective cohort study.
Shen SP; Liu Y; Qiu H; Tsai KY; Wu HC; Liang WM; Shu M; Chou FH
PLoS One; 2019; 14(9):e0221948. PubMed ID: 31487309
[TBL] [Abstract][Full Text] [Related]
6. Risk of fractures associated with treatment for benign prostate hyperplasia in men.
Vestergaard P; Rejnmark L; Mosekilde L
Osteoporos Int; 2011 Feb; 22(2):731-7. PubMed ID: 20552327
[TBL] [Abstract][Full Text] [Related]
7. Drug or symptom-induced depression in men treated with alpha 1-blockers for benign prostatic hyperplasia? A nested case-control study.
Clifford GM; Farmer RD
Pharmacoepidemiol Drug Saf; 2002; 11(1):55-61. PubMed ID: 11998552
[TBL] [Abstract][Full Text] [Related]
8. α-Blocker and Risk of Dementia in Patients with Benign Prostatic Hyperplasia: A Nationwide Population Based Study Using the National Health Insurance Service Database.
Tae BS; Jeon BJ; Choi H; Cheon J; Park JY; Bae JH
J Urol; 2019 Aug; 202(2):362-368. PubMed ID: 30840545
[TBL] [Abstract][Full Text] [Related]
9. [The risk of fracture with taking alpha blockers for treating benign prostatic hyperplasia].
Lee J; Choi NK; Jung SY; Kim YJ; Seong JM; Oh SJ; Park BJ
J Prev Med Public Health; 2009 May; 42(3):165-70. PubMed ID: 19491559
[TBL] [Abstract][Full Text] [Related]
10. The association of α-blockers and 5-α reductase inhibitors in benign prostatic hyperplasia with fractures.
Lim SY; Laengvejkal P; Panikkath R; Nugent K
Am J Med Sci; 2014 Jun; 347(6):463-71. PubMed ID: 24270079
[TBL] [Abstract][Full Text] [Related]
11. Dopaminergic drugs and the risk of hip or femur fracture: a population-based case-control study.
Arbouw ME; Movig KL; van Staa TP; Egberts AC; Souverein PC; de Vries F
Osteoporos Int; 2011 Jul; 22(7):2197-204. PubMed ID: 20967420
[TBL] [Abstract][Full Text] [Related]
12. Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery.
Bell CM; Hatch WV; Fischer HD; Cernat G; Paterson JM; Gruneir A; Gill SS; Bronskill SE; Anderson GM; Rochon PA
JAMA; 2009 May; 301(19):1991-6. PubMed ID: 19454637
[TBL] [Abstract][Full Text] [Related]
13. Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease.
Simmering JE; Welsh MJ; Liu L; Narayanan NS; Pottegård A
JAMA Neurol; 2021 Apr; 78(4):407-413. PubMed ID: 33523098
[TBL] [Abstract][Full Text] [Related]
14. Risk of Incident Antidepressant-Treated Depression Associated with Use of 5α-Reductase Inhibitors Compared with Use of α-Blockers in Men with Benign Prostatic Hyperplasia: A Population-Based Study Using the Clinical Practice Research Datalink.
Hagberg KW; Divan HA; Nickel JC; Jick SS
Pharmacotherapy; 2017 May; 37(5):517-527. PubMed ID: 28295443
[TBL] [Abstract][Full Text] [Related]
15. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study.
Pouwels S; Lalmohamed A; Souverein P; Cooper C; Veldt BJ; Leufkens HG; de Boer A; van Staa T; de Vries F
Osteoporos Int; 2011 Mar; 22(3):903-10. PubMed ID: 20585937
[TBL] [Abstract][Full Text] [Related]
16. Association between 5-alpha reductase inhibition and risk of hip fracture.
Jacobsen SJ; Cheetham TC; Haque R; Shi JM; Loo RK
JAMA; 2008 Oct; 300(14):1660-4. PubMed ID: 18840839
[TBL] [Abstract][Full Text] [Related]
17. Risk of hip/femur fractures in patients using antipsychotics.
Hugenholtz GW; Heerdink ER; van Staa TP; Nolen WA; Egberts AC
Bone; 2005 Dec; 37(6):864-70. PubMed ID: 16111927
[TBL] [Abstract][Full Text] [Related]
18. Use of anti-depressants and the risk of fracture of the hip or femur.
van den Brand MW; Pouwels S; Samson MM; van Staa TP; Thio B; Cooper C; Leufkens HG; Egberts AC; Verhaar HJ; de Vries F
Osteoporos Int; 2009 Oct; 20(10):1705-13. PubMed ID: 19238308
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Djavan B; Marberger M
Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
[TBL] [Abstract][Full Text] [Related]
20. The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years.
Kaplan SA; Te AE; Ikeguchi E; Santarosa RP
Br J Urol; 1997 Dec; 80(6):875-9. PubMed ID: 9439400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
